XBiotech Inc (XBIT)
6.83
+0.21
(+3.17%)
USD |
NASDAQ |
Nov 22, 16:00
6.88
+0.05
(+0.73%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 208.20M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 90.78% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 51.87 |
| Price to Book Value | 1.084 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 86.04% |
Profile
| XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States. |
| URL | http://www.xbiotech.com |
| Investor Relations URL | https://investors.xbiotech.com |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2025 (est.) |
| Last Earnings Release | Nov. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 15, 2021 |
Ratings
Profile
| XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States. |
| URL | http://www.xbiotech.com |
| Investor Relations URL | https://investors.xbiotech.com |
| HQ State/Province | Texas |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2025 (est.) |
| Last Earnings Release | Nov. 13, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jul. 15, 2021 |